<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01357538</url>
  </required_header>
  <id_info>
    <org_study_id>POFOBLE</org_study_id>
    <secondary_id>S67-OPH-081</secondary_id>
    <secondary_id>S67-OPH-081</secondary_id>
    <nct_id>NCT01357538</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Posiformin 2 % Eye Ointment in the Treatment of Blepharitis</brief_title>
  <official_title>Efficacy and Safety of Posiformin 2 % Eye Ointment in the Treatment of Blepharitis - a Multi-centre, Randomised, Double-masked, Parallel-group, Phase IV Comparison</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ursapharm Arzneimittel GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ursapharm Arzneimittel GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, randomised, double-masked, parallel-group, phase IV comparison of
      Posiformin 2 % eye ointment (active substance: bibrocathol) in the treatment of blepharitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Reduction of signs and symptoms of blepharitis
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Posiformin 2% in reduction of signs and symptoms of blepharitis</measure>
    <time_frame>14 days</time_frame>
    <description>Changes from baseline in the sumscore which comprises lid edema, lid erythema, debris, pouting of Meibomian glands by slit lamp examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in blepharitis signs and symptoms</measure>
    <time_frame>14 days</time_frame>
    <description>Changes between baseline and end of treatment in lid edema, lid erythema, debris, pouting of meibomian glands, ocular discomfort, antiseptic effect</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Blepharitis</condition>
  <condition>Signs and Symptoms</condition>
  <arm_group>
    <arm_group_label>Posiformin 2 %</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eye ointment applied to the eye lid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>corresponding vehicle, eye ointment applied to the eye lid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posiformin 2 %, bibrocathol</intervention_name>
    <description>A strip of 5 mm eye ointment applied 3 times per day to the eye lid</description>
    <arm_group_label>Posiformin 2 %</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>corresponding vehicle, eye ointment applied to the eye lid</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent

          -  ambulatory male and female patients 18 years of age or older

          -  summarised score of signs and symptoms of blepharitis of 15 or more at baseline

        Exclusion Criteria:

          -  different ocular conditions

          -  different system conditions

          -  several concomitant medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pavel A Bezdetko, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kharkov District Clinical Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kharkov District Clinical Hospital</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2011</study_first_submitted>
  <study_first_submitted_qc>May 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2011</study_first_posted>
  <last_update_submitted>May 19, 2011</last_update_submitted>
  <last_update_submitted_qc>May 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. P. A. Bezdetko</name_title>
    <organization>Kharkov District Clincial Hospital</organization>
  </responsible_party>
  <keyword>Bibrocathol</keyword>
  <keyword>eye ointment</keyword>
  <keyword>blepharitis</keyword>
  <keyword>eye lid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Signs and Symptoms</mesh_term>
    <mesh_term>Blepharitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

